Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Descriptor ID |
D011993
|
MeSH Number(s) |
D12.776.828.300
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in UAMS Profiles by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2024 | 2 | 2 | 4 | 2022 | 0 | 2 | 2 | 2021 | 1 | 1 | 2 | 2020 | 5 | 0 | 5 | 2019 | 1 | 0 | 1 | 2017 | 1 | 1 | 2 | 2016 | 1 | 0 | 1 | 2015 | 1 | 3 | 4 | 2014 | 4 | 6 | 10 | 2013 | 2 | 8 | 10 | 2012 | 1 | 3 | 4 | 2011 | 2 | 4 | 6 | 2010 | 3 | 5 | 8 | 2009 | 0 | 3 | 3 | 2008 | 2 | 4 | 6 | 2007 | 2 | 4 | 6 | 2006 | 1 | 5 | 6 | 2005 | 1 | 6 | 7 | 2004 | 1 | 8 | 9 | 2003 | 0 | 4 | 4 | 2002 | 1 | 13 | 14 | 2001 | 1 | 3 | 4 | 2000 | 0 | 3 | 3 | 1999 | 0 | 8 | 8 | 1998 | 2 | 3 | 5 | 1997 | 3 | 3 | 6 | 1996 | 1 | 1 | 2 | 1995 | 0 | 1 | 1 | 1994 | 0 | 5 | 5 | 1992 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles over the past ten years.
-
Birrer M, Li G, Yunokawa M, Lee JY, Kim BG, Oppermann CP, Zhou Q, Nishio S, Okamoto A, Wu X, Mileshkin L, Oaknin A, Ray-Coquard I, Hasegawa K, Jehl G, Vugmeyster Y, Zhang S, Bajars M, Yonemori K. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Sep 01; 10(9):1204-1211.
-
Mehta NK, Rakhra K, Meetze KA, Li B, Momin N, Chang JYH, Wittrup KD, Baeuerle PA, Michaelson JS. CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity. Cancer Immunol Res. 2024 Aug 01; 12(8):1022-1038.
-
Sharathkumar A, Carr J, Claassen D, Syrbu S, Bhagavathi S, Al-Huniti A, Modi A, Bates M, Mott SL. Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome. J Pediatr Hematol Oncol. 2024 07 01; 46(5):252-261.
-
Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024 05 01; 109(5):1514-1524.
-
Zaidman CM, Goedeker NL, Aqul AA, Butterfield RJ, Connolly AM, Crystal RG, Godwin KE, Hor KN, Mathews KD, Proud CM, Kula Smyth E, Veerapandiyan A, Watkins PB, Mendell JR. Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2024; 11(3):687-699.
-
ElSheikh RH, Chauhan MZ, Sallam AB. Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration. Biomolecules. 2022 11 03; 12(11).
-
Farrukh F, Chetram D, Al-Kali A, Foran J, Patnaik M, Badar T, Begna K, Hook C, Hogan W, McCullough KB, Mangaonkar A, He R, Gangat N, Tefferi A. Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. Am J Hematol. 2022 06 01; 97(6):E210-E214.
-
Nedosekin DA, Chen T, Ayyadevara S, Zharov VP, Shmookler Reis RJ. Label-free photothermal disruption of cytotoxic aggregates rescues pathology in a C. elegans model of Huntington's disease. Sci Rep. 2021 10 05; 11(1):19732.
-
Al-Huniti A, Rathi N, Modi A, Bhagavathi S, Mitten R, Sharathkumar AA. Up-front Treatment With Romiplostim in Children With Acquired Bone Marrow Failure: A Single Institutional Pediatric Case Series. J Pediatr Hematol Oncol. 2021 04 01; 43(3):e431-e435.
-
Chand DH, Zaidman C, Arya K, Millner R, Farrar MA, Mackie FE, Goedeker NL, Dharnidharka VR, Dandamudi R, Reyna SP. Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series. J Pediatr. 2021 04; 231:265-268.
-
Harada Y, Rao VK, Arya K, Kuntz NL, DiDonato CJ, Napchan-Pomerantz G, Agarwal A, Stefans V, Katsuno M, Veerapandiyan A. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve. 2020 10; 62(4):550-554.
-
Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy. Ann Pharmacother. 2020 10; 54(10):1001-1009.
-
Tremblay G, Dolph M, Roy AN, Said Q, Forsythe A. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States. Clin Ther. 2020 05; 42(5):860-872.e8.
-
Forsythe A, Schneider J, Pham T, Bhor M, Said Q, Allepuz A, Socorro O Portella MD, Kwon CS, Roy AN. Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists. J Comp Eff Res. 2020 05; 9(7):447-457.
-
Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM. Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol. 2019 07; 94(7):741-750.
-
Rodriguez A, Brown C, Badie B. Chimeric antigen receptor T-cell therapy for glioblastoma. Transl Res. 2017 09; 187:93-102.
-
Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB, Schnell MJ. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. J Virol. 2017 Jan 15; 91(2).
-
Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016 08; 63(8):1407-13.
-
Morshedi RG, Ricca AM, Wirostko BM. Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide. J Glaucoma. 2016 Mar; 25(3):291-300.
-
O'Connor HF, Lyon N, Leung JW, Agarwal P, Swaim CD, Miller KM, Huibregtse JM. Ubiquitin-Activated Interaction Traps (UBAITs) identify E3 ligase binding partners. EMBO Rep. 2015 Dec; 16(12):1699-712.
-
Ferdaoussi M, Dai X, Jensen MV, Wang R, Peterson BS, Huang C, Ilkayeva O, Smith N, Miller N, Hajmrle C, Spigelman AF, Wright RC, Plummer G, Suzuki K, Mackay JP, van de Bunt M, Gloyn AL, Ryan TE, Norquay LD, Brosnan MJ, Trimmer JK, Rolph TP, Kibbey RG, Manning Fox JE, Colmers WF, Shirihai OS, Neufer PD, Yeh ET, Newgard CB, MacDonald PE. Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional ? cells. J Clin Invest. 2015 Oct 01; 125(10):3847-60.
-
P?pin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, Coletti CM, Yu A, Castro CM, Birrer MJ, Gao G, Donahoe PK. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. Proc Natl Acad Sci U S A. 2015 Aug 11; 112(32):E4418-27.
-
Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol. 2015 Mar; 34(2):154-87.
-
Willett RA, Kudlyk TA, Lupashin VV. Expression of functional Myc-tagged conserved oligomeric Golgi (COG) subcomplexes in mammalian cells. Methods Mol Biol. 2015; 1270:167-77.
-
Larson CL, Beare PA, Voth DE, Howe D, Cockrell DC, Bastidas RJ, Valdivia RH, Heinzen RA. Coxiella burnetii effector proteins that localize to the parasitophorous vacuole membrane promote intracellular replication. Infect Immun. 2015 Feb; 83(2):661-70.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|